Regencell (RGC) promoted a traditional Chinese medicine approach to treating ADHD and autism. A small company with twelve employees, no approved or salable products, and no revenue said it was developing traditional Chinese medicine formulas for ADHD and autism. Then its stock exploded.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
A federal securities lawsuit filed against Regencell Bioscience Holdings Limited alleges that company executives concealed the risk of market manipulation while the stock surged nearly 49,000% before a Department of Justice investigation became public.
The complaint, filed on April 24, 2026, in the U.S. District Court for the District of Maryland, covers a class period running from October 28, 2024, through October 31, 2025. When the company disclosed that the DOJ had issued a subpoena investigating trading in its shares, the stock dropped $3.09 per share, or approximately 18.56%, on November 3, 2025.
Investors who purchased Regencell securities during the class period and suffered losses may wish to learn more about their eligibility to participate in this action.
A Hong Kong-Based Bioscience Company With Big Claims and Minimal Revenue
Regencell is an early-stage bioscience company incorporated in the Cayman Islands and headquartered in Causeway Bay, Hong Kong. The company focuses on researching and commercializing traditional Chinese medicine formulas for the treatment of attention-deficit/hyperactivity disorder and autism spectrum disorder, two conditions the complaint describes as generally considered incurable under current medical consensus.
Despite its stated ambitions, Regencell reported just twelve employees and no approved or commercially available products as of the filing date. The company has generated no revenue and has incurred operating losses since its formation. Research and development expenditures were approximately $0.95 million and $1.07 million for the fiscal years ended June 30, 2025, and 2024, respectively, a fraction of the billions the company itself cited as typical drug development costs.
Regencell is classified as a “controlled company” under Nasdaq rules. According to the complaint, as of June 30, 2025, 88.8% of Regencell’s shares were held by directors and executive officers, with 88.6% of those shares owned by Defendant Yat-Gai Au; the complaint further alleges that, at filing, 88.56% of shares were held by insiders, with the vast majority presumably still held by Au. As of the filing, Regencell carried a market capitalization of approximately $14 billion. According to the complaint, the Wall Street Journal observed that only 20 of the 261 companies in the Nasdaq Biotechnology Index had a greater market value, even though Regencell was not included in that index.
What the Lawsuit Says Defendants Failed to Tell Investors
The lawsuit alleges that throughout the class period, Regencell and its senior officers made materially false and misleading public statements by failing to disclose that the company was vulnerable to or subject to market manipulation. Defendants are also alleged to have concealed that this vulnerability exposed investors to significant financial risk and subjected the company to heightened regulatory scrutiny, governmental enforcement risk, and potential legal and reputational harm.
Rather than disclosing these risks, the complaint alleges that Defendants attributed extreme share price volatility to short-selling activity and unidentified third-party social media content. The suit contends that Defendants’ public filings contained generic risk disclosures that were not tailored to the actual, known risks facing the company’s stock.
Investors who followed developments in this case are encouraged to monitor further proceedings as they unfold.
Risk Warnings That the Complaint Says Missed the Mark
Regencell’s October 2024 annual filing on Form 20-F included standard market risk language warning that its shares “may be very thinly traded” and that volatility “could” result from various factors, including analyst projections, operating results, and general economic conditions. The filing also flagged the possibility of a “short squeeze” as a driver of potential price volatility.
Following the dramatic share price increase beginning in May 2025, Regencell filed interim financial statements in June 2025 that acknowledged extreme price and volume fluctuations but again attributed volatility primarily to short sellers and third-party media. The interim filing stated that the company believed a large proportion of its shares had been traded by short sellers, which may have increased pressure on supply and demand. The complaint argues these statements were materially misleading because they failed to address what role, if any, market manipulation had played in driving the extraordinary price movements.
How the Alleged Truth Came to Light
The central corrective disclosure came on October 31, 2025, when Regencell filed its annual report on Form 20-F, disclosing that it had received correspondence and a subpoena from the U.S. Department of Justice. The filing stated that the DOJ was conducting an investigation into the trading in Regencell’s ordinary shares and had requested documents and communications relating to corporate operational, financial, and accounting matters.
The company disclosed in the same filing that it expected to incur high legal costs in connection with the investigation and warned that it could be required to pay fines, penalties, damages, or settlement costs potentially in excess of its insurance coverage. Following this disclosure, Regencell’s ordinary share price fell from approximately $16.65 to $13.56 per share, a decline of $3.09, or 18.56%, to close on November 3, 2025.
Why Shareholders Who Traded During This Period Should Take Note
The complaint contends that between October 2024 and October 2025, Regencell’s public statements created an artificially inflated picture of the company’s risk profile by omitting material information about its susceptibility to market manipulation and the resulting legal exposure. Investors who purchased shares during that window did so without knowing, the lawsuit argues, that Regencell was vulnerable to or subject to market manipulation and faced heightened regulatory and governmental scrutiny and enforcement risk.
The stock’s extraordinary rise from less than $0.30 per share to a class period high of $78.00 in June 2025, followed by a sharp decline, forms the backdrop for the damages alleged on behalf of the proposed class. Shareholders who bought and held shares at elevated prices and then absorbed losses following the November 2025 disclosure may have a particular interest in the outcome of this case.
The Federal Securities Laws Behind the Claims
The plaintiff asserts violations of Section 10(b) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder, which prohibit fraudulent statements and material omissions in connection with the purchase or sale of securities. Section 20(a) of the Exchange Act is also cited against Defendants Au and Chan as controlling persons of Regencell who allegedly directed or permitted the misleading disclosures.
The plaintiff further alleges that Regencell violated SEC Regulation S-K Items 105 and 303, which require companies to disclose material risk factors and known trends likely to have a material impact on the business.
Investors who believe they may have suffered losses during the class period are encouraged to consult legal resources to understand their rights.
About Levi & Korsinsky, LLP
Levi & Korsinsky, LLP is a nationally recognized securities litigation firm representing investors in complex shareholder actions. The firm has extensive expertise and a team of over 70 employees to serve our clients. Attorney advertising. Prior results do not guarantee similar outcomes.
Disclaimer: This article is provided for informational purposes only and does not constitute legal advice. No attorney-client relationship is created by reading this article. Past results do not guarantee similar outcomes.